Note: All submitted events must be approved before they appear in the calendar.
PCOS Externally-Led Patient-Focused Drug Development Meeting (PCOS EL-PFDD Meeting) Presented by PCOS Challenge: The National Polycystic Ovary Syndrome Association
About Polycystic Ovary Syndrome (PCOS)
PCOS is a serious genetic, hormone, metabolic, and reproductive disorder that affects up to 15% of women. PCOS can lead to lifelong complications, infertility, anxiety, depression and other psychosocial disorders, obesity, severe hair and skin issues, endometrial cancer, type 2 diabetes, cardiovascular disease, stroke, nonalcoholic fatty liver disease, and other major conditions. Despite the significant health impact and $15 billion annual economic burden, there have never been any FDA-approved treatments specifically for PCOS.
About the Meeting – Accelerating New Treatments for PCOS
The PCOS EL-PFDD Meeting is a listening session for the FDA, clinicians, researchers, and product developers to hear directly from PCOS patients about their lived experience with PCOS and their perspectives on current and future treatments and clinical trials. The insights from this meeting will help guide the FDA’s decision-making processes both in drug development and marketing application reviews.
Benefits for Patients of Attending
Participating in this meeting grants patients the unprecedented opportunity to influence the development of PCOS-focused treatments and diagnostics. Benefits include:
1. Directly informing stakeholders about the daily impacts and health effects of living with PCOS.
2. Sharing perspectives on the effectiveness of existing treatment and management options.
3. Highlighting patients’ unmet needs and priorities for new treatments.
Benefits for Pharma/Industry Representatives Attending
For industry stakeholders, attending this meeting is a strategic move toward patient-centered innovation. Benefits encompass:
1. Gaining an in-depth understanding of patients’ experiences, symptom burden, and treatment history.
2. Learning the multiple factors influencing patients’ treatment choices and trial participation.
3. Identifying unmet needs in PCOS care to drive more effective drug development.
4. Obtaining insights to design patient-centered clinical trials tailored to meet the needs and priorities of the PCOS community.
Sponsor opportunities are available.
For more information and to register, visit the PCOS PFDD Website.